Strs Ohio Invests $12.91 Million in Hologic, Inc. $HOLX

Key Points

• Strs Ohio has acquired a new stake in Hologic, Inc. (NASDAQ: HOLX) with 209,000 shares valued at approximately $12.91 million, constituting about 0.09% of the company.
• Hologic reported quarterly earnings of $1.08 EPS, exceeding analysts' expectations, with revenue of $1.02 billion, up 1.2% year-over-year.
• Multiple brokerages have increased their price targets for Hologic, with an average target of $78.00 and a consensus rating of "Moderate Buy".

Strs Ohio bought a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm bought 209,000 shares of the medical equipment provider's stock, valued at approximately $12,910,000. Strs Ohio owned about 0.09% of Hologic at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT bought a new position in shares of Hologic in the first quarter worth about $34,000. Allworth Financial LP increased its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the first quarter worth approximately $42,000. Larson Financial Group LLC boosted its position in shares of Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 722 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the fourth quarter worth $49,000. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on HOLX. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Argus upgraded shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, August 18th. Morgan Stanley lifted their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday. Finally, Evercore ISI lifted their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $78.00.

Hologic Price Performance

Shares of HOLX traded down $0.65 during mid-day trading on Monday, reaching $63.80. The company had a trading volume of 1,276,134 shares, compared to its average volume of 1,330,759. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company has a market capitalization of $14.19 billion, a P/E ratio of 26.47, a P/E/G ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company's 50-day moving average is $66.42 and its 200-day moving average is $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm earned $1.06 EPS. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.